Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma

Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma

Collecting duct carcinoma (CDC) is a rare, extremely aggressive form of renal cancer. Recently, immune checkpoint inhibitors (ICI), anti-programmed death-1 (PD-1) antibody, and anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibody were approved for use against metastatic renal cell carc...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tetsuya Danno, Shohei Iwata, Fusako Niimi, Sachi Honda, Haruka Okada, Takeshi Azuma
Format:	Article
Language:	English
Published:	Wiley 2021-01-01
Series:	Case Reports in Urology
Online Access:	http://dx.doi.org/10.1155/2021/9936330
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma
by: Taylor C. Peak, et al.
Published: (2020-01-01)

Retinal Toxicity after Initial Administration of Nivolumab and Ipilimumab
by: Adnan Kilani, et al.
Published: (2023-01-01)

Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association
by: Alexander D. Woods, MD, et al.
Published: (2025-03-01)

Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
by: Gérald E. Piérard, et al.
Published: (2012-01-01)

Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma
by: Maki Todo, et al.
Published: (2025-02-01)

Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma
by: Mahdieh Fazel, et al.
Published: (2019-01-01)

Lambert-Eaton Myasthenic Syndrome Secondary to Nivolumab and Ipilimumab in a Patient with Small-Cell Lung Cancer
by: Kavita Agrawal, et al.
Published: (2019-01-01)

Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
by: A. A. Formozo, et al.
Published: (2021-01-01)

Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
by: Bartosz Chmielowski
Published: (2013-01-01)

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
by: Enriqueta Felip, et al.
Published: (2024-02-01)

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
by: Satoshi Endo, et al.
Published: (2025-01-01)

Acute Interstitial Nephritis in a Patient with Non-Small Cell Lung Cancer under Immunotherapy with Nivolumab
by: Panagiotis I. Georgianos, et al.
Published: (2019-01-01)

Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab
by: Anne Rogiers, et al.
Published: (2020-01-01)

Efficacy of Nivolumab in a Patient with Metastatic Renal Cell Carcinoma and End-Stage Renal Disease on Dialysis: Case Report and Literature Review
by: Jawaher Ansari, et al.
Published: (2018-01-01)

Collecting Duct Carcinoma of the Native Kidney in a Renal Transplant Recipient
by: Ian Zheng, et al.
Published: (2017-01-01)

Progress in immunotherapy for brain metastatic melanoma
by: Shicheng Zheng, et al.
Published: (2025-01-01)

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
by: Wei Chen, et al.
Published: (2025-01-01)

Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
by: Hilin Yildirim, et al.
Published: (2025-02-01)

Engineered ipilimumab variants that bind human and mouse CTLA-4
by: Brett Robison, et al.
Published: (2025-12-01)

Complex Monitoring of Biochemical and Radionuclide Parameters in Patients with Metastatic Renal Cell Carcinoma during Immunotherapy
by: M. S. Sayapina, et al.
Published: (2017-01-01)

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
by: Massimo Ralli, et al.
Published: (2020-01-01)

Surgery lengthens survival for collecting duct carcinoma: analysis of hospital-based cancer registry data in Japan
by: Shuya Kandori, et al.
Published: (2025-01-01)

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors
by: Matthew Burge, et al.
Published: (2023-01-01)

A Severe Case of Ipilimumab-Induced Ileocolitis Refractory to Glucocorticosteroids and Infliximab
by: Behdod Poushanchi, et al.
Published: (2018-01-01)

Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab
by: Nora Chokr, et al.
Published: (2018-01-01)

Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy
by: Antonio Faieta, et al.
Published: (2021-01-01)

Tubulocystic Carcinoma of the Bile Duct
by: Masahiro Takeuchi, et al.
Published: (2018-01-01)

A Case of Nivolumab-Induced Severe Mononeuropathy Multiplex and Rhabdomyolysis
by: Katsuya Sakai, et al.
Published: (2017-01-01)

Collecting duct NCOR1 controls blood pressure by regulating mineralocorticoid receptor
by: Ke Sun, et al.
Published: (2025-02-01)

Efficacy and safety of immunotherapy in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: a multicenter retrospective study
by: Xiongwen Yang, et al.
Published: (2025-01-01)

Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma
by: Brenen P. Swofford, et al.
Published: (2017-01-01)

Immunotherapy for Metastatic Melanoma with Right Atrial Involvement in a Patient with Rheumatoid Arthritis
by: Zachary Benson, et al.
Published: (2017-01-01)

Nivolumab-Induced Encephalitis in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome
by: Benjamin Chaucer, et al.
Published: (2018-01-01)

Stratification system with dual human endogenous retroviruses for predicting immunotherapy efficacy in metastatic clear-cell renal cell carcinoma
by: Li Xu, et al.
Published: (2025-01-01)

Combination therapy of low-dose radiotherapy and immunotherapy in advanced metastatic nasopharyngeal carcinoma: a case report and literature review
by: Chun-Qiao Chen, et al.
Published: (2025-01-01)

Bellini Duct Carcinoma Misdiagnosed with Urothelial Papillary Carcinoma
by: Joey El Khoury, et al.
Published: (2020-01-01)

Enhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects
by: Zahid Rafiq, et al.
Published: (2025-01-01)

Simultaneous Papillary Carcinoma in Thyroglossal Duct Cyst and Thyroid
by: Gustavo Cancela e Penna, et al.
Published: (2017-01-01)

Gallbladder Carcinoma Associated with Anomalous Pancreaticobiliary Duct Junction
by: Chang Moo Kang, et al.
Published: (2007-01-01)

Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature
by: Nicholas Gravbrot, et al.
Published: (2019-01-01)